Metis TechBio in Discovery Pact Potentially Worth More Than $1 Billion With Eli Lilly
By Colin Kellaher
Metis TechBio has formed a collaboration with Eli Lilly that is potentially worth more than $1 billion to the Hong Kong-listed biotech.
Metis on Monday said the companies will work with to discover novel lipid nanoparticle-based delivery solutions designed to enable tissue-specific delivery of therapeutic modalities.
Metis said it will use its proprietary, AI-driven ionizable lipid discovery and optimization platform to develop delivery technologies with the potential to improve targeting and biodistribution of lipid nanoparticle-based delivery, while Indianapolis drugmaker Eli Lilly will contribute its expertise in drug discovery, development and commercialization.
Metis said it will receive an upfront payment in the low double-digit millions of dollars and will be eligible for up to about $1.1 billion in development, regulatory and commercial milestone payments, along with royalties on product sales.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 19, 2026 08:24 ET (12:24 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
United States